-
Toripalimab For Extensive-Stage Small Cell Lung Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Ayse Ece Cali Daylan,Daniel Morgensztern,Saiama N Waqar
-
Concerns Regarding Sample Size and Credibility of Progression-Free Survival Results. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Xiaoling Xu,Lisha Ye,Yaping Xu
-
Concerns Regarding Sample Size and Credibility of Progression-Free Survival Results-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Song Dong,Hong-Hong Yan,Yi-Long Wu
-
Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Ying Cheng, Wei Zhang, Lin Wu, Caicun Zhou, Donglin Wang, Bing Xia, Minghong Bi, Xiuhua Fu, Chong Li, Dongqing Lv, Yanqiu Zhao, Gongyan Chen, Tienan Yi, Jianan Huang, Min Li, Runxiang Yang, Xiaoping Huang, Ye Wang, Mingjun Zhang, Yueyin Pan, Yilan Sun, Sheng Hu, Xiqin Zhang, Min Zhou, Jian Fang, Faguang Jin, Yunpeng Liu, Yinyin Li, Zhihong Zhang, Jie Hu, Laiyu Liu, Rui Wang, Yan Li, Kangsheng Gu, Cuimin
ImportancePatients with extensive-stage small cell lung cancer (ES-SCLC) have poor prognoses and unmet medical needs.ObjectiveTo evaluate the efficacy and safety of toripalimab plus etoposide and platinum-based chemotherapy (EP) vs placebo plus EP as a first-line treatment for patients with ES-SCLC.Design, Setting, and ParticipantsThis multicenter, double-blind, placebo-controlled phase 3 randomized
-
Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Tonny Studsgaard Petersen, Kristian Karstoft, Freja Karuna Hemmingsen Sørup, Marie Lund, Allan Cramer
This cohort study investigates the regulatory fate in the European Union for drugs that received accelerated approval for cancer indications in the US.
-
Advancing Global Pharmacoequity in Oncology JAMA Oncol. (IF 22.5) Pub Date : 2024-11-14 Parsa Erfani, Ruth L. Okediji, Vivienne Mulema, Edward R. Scheffer Cliff, Kwanele Asante-Shongwe, Brittany L. Bychkovksy, Temidayo Fadelu
ImportanceLimited availability and affordability of cancer drugs contribute to staggering disparities in cancer survival between high-income and low- and middle-income countries (LMICs). As infrastructure for cancer care rapidly develops, there is an urgent need to reduce prices and improve access to cancer medicines in LMICs to advance pharmacoequity globally.ObservationsPrior strategies to expand
-
PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-07 Marco Donia,Inge Marie Svane
-
PD-L1 Expression for Tailoring Treatment in Advanced Melanoma-It Is Never That Easy. JAMA Oncol. (IF 22.5) Pub Date : 2024-11-07 Latif Karahan,Mutlu Hayran,Omer Dizdar
-
Financial Toxicity Among Asian American Cancer Survivors JAMA Oncol. (IF 22.5) Pub Date : 2024-11-07 Stephanie Wang, Fumiko Chino, Edward Christopher Dee
This Viewpoint highlights financial toxicity specific to Asian American cancer survivors and presents steps forward within the framework of the social ecological model of health, considering individual, interpersonal, community, and policy-level dimensions.
-
Equecabtagene Autoleucel in Patients With Relapsed or Refractory Multiple Myeloma JAMA Oncol. (IF 22.5) Pub Date : 2024-11-07 Chunrui Li, Keshu Zhou, Yongxian Hu, Dehui Zou, Lijuan Chen, Bing Chen, Jing Liu, Xi Zhang, Hanyun Ren, Kai Hu, Peng Liu, Jian-Qing Mi, Zhenyu Li, Kaiyang Ding, Di Wang, Wen Wang, Songbai Cai, Jianyong Li, Yongping Song, He Huang, Lugui Qiu
ImportanceEquecabtagene autoleucel (eque-cel), a fully human-derived B-cell maturation antigen-targeting chimeric antigen receptor (CAR) T-cell therapy, has exhibited potential for the treatment of relapsed or refractory multiple myeloma (RRMM), and further investigation in a larger cohort is necessary.ObjectiveTo evaluate whether eque-cel can benefit patients with RRMM and determine the overall response
-
Long-Term Adverse Effects and Complications After Prostate Cancer Treatment JAMA Oncol. (IF 22.5) Pub Date : 2024-11-07 Joseph M. Unger, Cathee Till, Catherine M. Tangen, Dawn L. Hershman, Phyllis J. Goodman, Michael LeBlanc, William E. Barlow, Riha Vaidya, Lori M. Minasian, Howard L. Parnes, Ian M. Thompson
ImportanceDue to the often indolent nature of prostate cancer (PCA), treatment decisions must weigh the risks and benefits of cancer control with those of treatment-associated morbidities.ObjectiveTo characterize long-term treatment-related adverse effects and complications in patients treated for PCA compared to a general population of older males.Design, Setting, and ParticipantsThis cohort study
-
Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-31 Wade T Swenson
-
Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-31 Jiatong Ding,Shuhang Wang,Ning Li
-
Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis JAMA Oncol. (IF 22.5) Pub Date : 2024-10-31 Paul M. Cinciripini, George Kypriotakis, Janice A. Blalock, Maher Karam-Hage, Diane M. Beneventi, Jason D. Robinson, Jennifer A. Minnix, Graham W. Warren
ImportanceSmoking after a cancer diagnosis increases mortality and risk for a second cancer.ObjectiveTo determine the association between time of entry into a smoking cessation intervention following a cancer diagnosis and survival outcomes.Design, Setting, and ParticipantsUsing a prospective cohort study design, patients with cancer who smoked and received cessation treatment were assessed at 3 months
-
Effects of the Oncology Industrial Complex on Academic Cancer Centers JAMA Oncol. (IF 22.5) Pub Date : 2024-10-31 S. Gail Eckhardt, Leonidas C. Platanias
This Viewpoint outlines the missions of academic cancer centers and how they are being affected by the oncology industrial complex along with challenges and suggestions for an aligned way forward.
-
Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma JAMA Oncol. (IF 22.5) Pub Date : 2024-10-31 Jann N. Sarkaria, Karla V. Ballman, Sani H. Kizilbash, Erik P. Sulman, Caterina Giannini, Bret B. Friday, Nicholas A. Butowski, Nimish A. Mohile, David E. Piccioni, James D. Battiste, Jan Drappatz, Jian L. Campian, Sandeep Mashru, Kurt A. Jaeckle, Barbara J. O’Brien, Jesse G. Dixon, Brian F. Kabat, Nadia L. Laack, Leland S. Hu, Timothy Kaufmann, Priya Kumthekar, Benjamin M. Ellingson, S. Keith Anderson
ImportanceThe prognosis for patients with glioblastoma is poor following standard therapy with surgical resection, radiation, temozolomide, and tumor-treating fields.ObjectivesTo evaluate the combination of veliparib and temozolomide in glioblastoma based on preclinical data demonstrating significant chemosensitizing effects of the polyadenosine diphosphate-ribose polymerase 1/2 inhibitor veliparib
-
Anti-Programmed Death Ligand 1 Plus Targeted Therapy in Anaplastic Thyroid Carcinoma: A Nonrandomized Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-24 Maria E Cabanillas,Ramona Dadu,Renata Ferrarotto,Maria Gule-Monroe,Suyu Liu,Bryan Fellman,Michelle D Williams,Mark Zafereo,Jennifer R Wang,Charles Lu,Matthew Ning,Brian A McKinley,Scott E Woodman,Dzifa Duose,Gary B Gunn,Naifa L Busaidy,
Importance Anaplastic thyroid carcinoma (ATC) is a rare and lethal cancer. Although progress has been made in recent years in patients with mutated BRAF tumors, those who respond initially eventually die of their disease; furthermore, there are no approved therapies for non-BRAF mutated tumors. Objective To determine whether treatment with matched-targeted therapy plus immune checkpoint inhibitors
-
Hairy Kidneys and Sclerotic Bone Lesions JAMA Oncol. (IF 22.5) Pub Date : 2024-10-24 Juan Esteban Velez-Hernandez, Julia T. Geyer, Mateo Mejia Saldarriaga
A 72-year-old man with a history of polycythemia vera (positive for JAK2 V617F) presented with several months of functional decline and weight loss. An 18F-fluorodeoxyglucose positron emission tomography/computed tomography showed soft tissue infiltrates and sclerosis of the perirenal spaces with fluorodeoxyglucose uptake. What is your diagnosis?
-
Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-24 Hajime Asahina,Yoko Tsukita,Takehiro Tozuka
-
Dual Immune Checkpoint Inhibition in Patients With Aggressive Thyroid Carcinoma JAMA Oncol. (IF 22.5) Pub Date : 2024-10-24 Kartik Sehgal, Theodora Pappa, Kee-Young Shin, Julia Schiantarelli, Mofei Liu, Cora Ricker, Naomi R. Besson, Stephanie M. Jones, Emma L. Welsh, Kathleen L. Pfaff, Justine A. Barletta, Jihye Park, Brendan Reardon, Gerard M. Doherty, Erik K. Alexander, Scott J. Rodig, David A. Barbie, Anne O’Neill, Eliezer Van Allen, Robert I. Haddad, Jochen H. Lorch
ImportanceAggressive thyroid carcinoma, including radioiodine refractory (RAIR) differentiated thyroid carcinoma (DTC), medullary thyroid carcinoma (MTC), and anaplastic thyroid carcinoma (ATC), are associated with significant morbidity and mortality and have limited therapeutic options. Distinct immune profiles have been identified in thyroid cancer subtypes suggesting they may be susceptible to immune
-
Cancer Drug Access and Innovation Under the Inflation Reduction Act—A Balancing Act JAMA Oncol. (IF 22.5) Pub Date : 2024-10-24 Stacie B. Dusetzina, Frank S. David
This Viewpoint explores whether the Inflation Reduction Act’s provisions and price negotiations could affect investment in trials of new oncology therapies or indications.
-
Impacts of Immunotherapy on Patients With Aggressive Thyroid Carcinomas. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-24 Alfred King-Yin Lam
-
Chemoimmunotherapy in Older Adults With Non-Small Cell Lung Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-24 Hengjia Tu,Yuzhuo Zhang,Zhixuan You
-
Considerations of Lay Health Worker Intervention Among Patients With Advanced Cancer-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-17 Manali I Patel
-
Considerations of Lay Health Worker Intervention Among Patients With Advanced Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-17 Kai Kang,Yijun Wu
-
Diet Quality, Dietary Inflammatory Potential, and Risk of Prostate Cancer Grade Reclassification JAMA Oncol. (IF 22.5) Pub Date : 2024-10-17 Zhuo Tony Su, Mufaddal Mamawala, Patricia K. Landis, Claire M. de la Calle, Nitin Shivappa, Michael Wirth, James R. Hébert, Christian P. Pavlovich, Bruce J. Trock
ImportanceIt remains unclear whether diet may influence the risk of prostate cancer grade reclassification in men undergoing active surveillance.ObjectiveTo assess the association of diet quality and dietary inflammatory potential with prostate cancer grade reclassification during active surveillance.Design, Setting, and ParticipantsThis prospective cohort study included men diagnosed with grade group
-
Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-17 Omar El-Taji,Ashwin Sachdeva
-
Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-17 Nathalie Gaspar,Giun-Yi Hung,Sandra J Strauss,Quentin Campbell-Hewson,Filemon S Dela Cruz,Julia L Glade Bender,Kyung-Nam Koh,Sarah B Whittle,Godfrey Chi-Fung Chan,Nicolas U Gerber,Sauli Palmu,Daniel A Morgenstern,Alessandra Longhi,Fredrik Baecklund,Jun Ah Lee,Franco Locatelli,Catalina Márquez Vega,Katherine A Janeway,Geoffrey McCowage,Martin G McCabe,Behzad Bidadi,Jie Huang,Jodi McKenzie,Chinyere E
Importance The combination of ifosfamide and etoposide (IE) is commonly used to treat relapsed or refractory osteosarcoma; however, second-line treatment recommendations vary across guidelines. Objective To evaluate whether the addition of lenvatinib to IE (LEN-IE) improves outcomes in children and young adults with relapsed or refractory osteosarcoma. Design, Setting, and Participants The OLIE phase
-
Staging and Prognosis of Nasopharyngeal Cancer: The Time for Change Is Now. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Sweet Ping Ng,Darrion Mitchell
-
Differences in Sentinel Node Biopsy and Targeted Axillary Dissection Following Neoadjuvant Chemotherapy. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Mangesh A Thorat
-
Differences in Sentinel Node Biopsy and Targeted Axillary Dissection Following Neoadjuvant Chemotherapy-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Giacomo Montagna,Monica Morrow,Walter P Weber
-
Implementing Resource-Stratified Guidelines in LMICs—More Issues Than Solutions JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Shweta Baral
This Viewpoint discusses the importance of formulating more stable local treatment guidelines because international guidelines and even resource-stratified guidelines may not be as applicable in low- to middle-income countries.
-
Ninth Version of the AJCC and UICC Nasopharyngeal Cancer TNM Staging Classification JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Jian-Ji Pan, Hai-Qiang Mai, Wai Tong Ng, Chao-Su Hu, Jin-Gao Li, Xiao-Zhong Chen, James C. H. Chow, Edwin Wong, Victor Lee, Ling-Yu Ma, Qiao-Juan Guo, Qin Liu, Li-Zhi Liu, Ting-Ting Xu, Xiao-Chang Gong, Meng-Yun Qiang, Kwok-Hung Au, Tsz-Chim Liu, Chi Leung Chiang, You-Ping Xiao, Shao-Jun Lin, Yun-Bin Chen, Shan-Shan Guo, Charlene H. L. Wong, Lin-Quan Tang, Zhi-Yuan Xu, Yi-Zhen Jia, Wen-Sa Peng, Li-Ping
ImportanceAccurate staging is a fundamental step in treating patients with nasopharyngeal carcinoma (NPC) worldwide; this is crucial not only for prognostication, but also for guiding treatment decisions. The American Joint Committee on Cancer (AJCC)/Union for International Cancer Control (UICC) tumor-node-metastasis (TNM) system is the global language for clinicians, researchers, and cancer registries
-
Natural Language Processing–Assessed Unmet Medical and Social Needs in Cancer Crowdfunding Stories JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Zhiyuan Zheng, Shaojun Yu, Farhad Islami, Matthew P. Banegas, Jingxuan Zhao, Jing Zhang, Fumiko Chino, K. Robin Yabroff
This cross-sectional study uses a large natural language processing model to examine unmet medical and social needs based on cancer-related fundraising stories in the US.
-
Endometrial Cancer Classification and Management in the Molecular Subtyping Era JAMA Oncol. (IF 22.5) Pub Date : 2024-10-10 Anjelica Hodgson, Kathy Han
A 65-year-old woman presented with a 6-month history of postmenopausal vaginal bleeding, and endometrial biopsy showed grade 2 endometrioid adenocarcinoma. What would you do next?
-
Ensuring Safety and Consistency in Artificial Intelligence Chatbot Responses. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-03 Lingxuan Zhu,Weiming Mou,Peng Luo
-
Ensuring Safety and Consistency in Artificial Intelligence Chatbot Responses-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-03 David Chen,Srinivas Raman
-
Moving the Needle on Equity in Prostate Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-10-03 Deborah C Marshall
-
Fracture Risk Prediction Using the Fracture Risk Assessment Tool in Individuals With Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-10-03 Carrie Ye, William D. Leslie, Saeed Al-Azazi, Lin Yan, Lisa M. Lix, Piotr Czaykowski, Eugene V. McCloskey, Helena Johansson, Nicholas C. Harvey, John A. Kanis, Harminder Singh
ImportanceThe Fracture Risk Assessment Tool (FRAX) is a fracture risk prediction tool for 10-year probability of major osteoporotic fracture (MOF) and hip fracture in the general population. Whether FRAX is useful in individuals with cancer is uncertain.ObjectiveTo determine the performance of FRAX for predicting incident fractures in individuals with cancer.Design, Setting, and ParticipantsThis retrospective
-
Biomarkers to Inform Prognosis and Treatment for Unresectable or Metastatic GEP-NENs JAMA Oncol. (IF 22.5) Pub Date : 2024-10-03 Jonathan M. Loree, David Chan, Jennifer Lim, Heather Stuart, Nicolas Fidelman, Jonathan Koea, Jason Posavad, Meredith Cummins, Sarah Doucette, Sten Myrehaug, Boris Naraev, Dale L. Bailey, Andrew Bellizzi, David Laidley, Veronica Boyle, Rachel Goodwin, Jaydi del Rivero, Michael Michael, Janice Pasieka, Simron Singh
ImportanceEvidence-based treatment decisions for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) require individualized patient-centered decision-making that accounts for patient and cancer characteristics.ObjectiveTo create an accessible guidance document to educate clinicians and patients on biomarkers informing prognosis and treatment in unresectable or metastatic GEP-NENs.MethodsA
-
Prevalence and Factors Associated With Prostate Cancer Among Transgender Women JAMA Oncol. (IF 22.5) Pub Date : 2024-10-03 Celeste Manfredi, Antonio Franco, Francesco Ditonno, Eugenio Bologna, Leslie Claire Licari, Costantino Leonardo, Alessandro Antonelli, Cosimo De Nunzio, Edward E. Cherullo, Marco De Sio, Riccardo Autorino
ImportanceEvidence on prostate cancer (PCa) in transgender women is very limited; data are needed to reduce gender disparities in both PCa knowledge and health care.ObjectiveTo evaluate the prevalence of PCa among transgender women in the US and assess the factors associated with PCa, and factors associated with biochemical recurrence (BCR) and bone metastases (BM) secondary to PCa in the transgender
-
Mismatch Repair and Microsatellite Testing for Individuals With Colorectal Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-10-03 Totadri Dhimal, Fernando Colugnati, Bailey K. Hilty Chu, Anthony Loria, Paula Cupertino, Daniel Mulkerin, Fergal J. Fleming
This cohort study examines the institution-level and patient-level factors associated with mismatch repair and microsatellite testing for individuals with colorectal cancer.
-
Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-09-26 Leisheng Zhang,Jing Li,Liang Guo
-
Meta-Analysis Methods for Neoadjuvant Chemoimmunotherapy for Non-Small Cell Lung Cancer-Reply. JAMA Oncol. (IF 22.5) Pub Date : 2024-09-26 Mark Sorin,Connor Prosty,Jonathan D Spicer
-
Complete Response to Locoregional Therapy Plus Immunotherapy for Hepatocellular Carcinoma JAMA Oncol. (IF 22.5) Pub Date : 2024-09-26 Chi Leung Chiang, Kenneth Sik Kwan Chan, Keith Wan Hang Chiu, Francis Ann Shing Lee, Wenqi Chen, Natalie Sean Man Wong, Ryan Lok Man Ho, Venus Wan Yan Lee, Kwan Man, Feng Ming (Spring) Kong, Albert Chi Yan Chan
ImportancePrevious studies showed that 42% to 50% of patients with locally advanced hepatocellular carcinoma (HCC) achieved complete remission (CR) after combined locoregional therapy (LRT) plus immunotherapy (IO). However, data on predictors of CR and long-term clinical outcomes without surgery and after discontinuation of IO are lacking.ObjectiveTo assess the long-term clinical outcomes among patients
-
How Can Guidelines Give Clearer Guidance on Prostate Cancer Screening? JAMA Oncol. (IF 22.5) Pub Date : 2024-09-26 Sigrid V Carlsson,William K Oh
-
Oral Microbiome and Subsequent Risk of Head and Neck Squamous Cell Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-09-26 Soyoung Kwak, Chan Wang, Mykhaylo Usyk, Feng Wu, Neal D. Freedman, Wen-Yi Huang, Marjorie L. McCullough, Caroline Y. Um, Martha J. Shrubsole, Qiuyin Cai, Huilin Li, Jiyoung Ahn, Richard B. Hayes
ImportanceThe oral microbiota may be involved in development of head and neck squamous cell cancer (HNSCC), yet current evidence is largely limited to bacterial 16S amplicon sequencing or small retrospective case-control studies.ObjectiveTo test whether oral bacterial and fungal microbiomes are associated with subsequent risk of HNSCC development.Design, Setting, and ParticipantsProspective nested
-
Recurrent Fevers in a Patient With Splenomegaly. JAMA Oncol. (IF 22.5) Pub Date : 2024-09-26 Darren D'Souza,Braulio Cuesta,Jennie Y Law
-
Stereotactic Body Radiotherapy for Medically Inoperable Early-Stage Non-Small Cell Lung Cancer. JAMA Oncol. (IF 22.5) Pub Date : 2024-09-19 Chen Hu
-
Transperineal vs Transrectal Prostate Biopsy-The PREVENT Randomized Clinical Trial. JAMA Oncol. (IF 22.5) Pub Date : 2024-09-19 Jim C Hu,Melissa Assel,Mohammad E Allaf,Andrew J Vickers,Behfar Ehdaie,Andrew J Cohen,David A Green,Ahmed Ghazi,Benjamin T Ristau,Keith J Kowalczyk,Arvin K George,Hiten D Patel,Jeffrey S Montgomery,Misop Han,Michael Rezaee,Christian P Pavlovich,Neal A Patel,Ashley E Ross,Shilajit D Kundu,Gerald J Wang,Jonathan E Shoag,Nirmish Singla,Kristian Stensland,Michael A Gorin,Anthony J Schaeffer,Edward M Schaeffer
-
Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-09-19 Randy F. Sweis, Pablo Gajate, Rafael Morales-Barrera, Jae-Lyun Lee, Andrea Necchi, Filippo de Braud, Nicolas Penel, Viktor Grünwald, Marco Maruzzo, Johannes Meran, Tatiane Cristine Ishida, Weichao Bao, Yinghui Zhou, Peter Ellinghaus, Jonathan E. Rosenberg
ImportanceThe oral pan–fibroblast growth factor receptor inhibitor rogaratinib previously demonstrated encouraging safety and efficacy in a phase 1 study of patients with urothelial cancer (UC) overexpressing FGFR messenger RNA (mRNA).ObjectiveTo evaluate the safety, pharmacokinetics, and preliminary efficacy of rogaratinib in combination with the programmed cell death 1 ligand 1 (PD-L1) inhibitor
-
Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-09-19 Naifei Chen, Chengfei Pu, Lingling Zhao, Wei Li, Chang Wang, Ruihong Zhu, Tingting Liang, Chao Niu, Xi Huang, Haiyang Tang, Yizhuo Wang, Hang Yang, Beibei Jia, Xianyang Jiang, Guiting Han, Wensheng Wang, Dongqi Chen, Yiming Wang, Eric K. Rowinsky, Eugene Kennedy, Victor X. Lu, Guozhen Cui, Zhao Wu, Lei Xiao, Jiuwei Cui
ImportanceChimeric antigen receptor (CAR) T-cell therapy (CART) has transformed the treatment landscape of hematologic cancer, but has negligible effects for adult solid cancers. In this trial, an autologous CAR T-cell product demonstrated antitumor activity in heavily pretreated patients with metastatic colorectal cancer (mCRC).ObjectiveTo evaluate the safety and efficacy of guanylate cyclase-C (GCC19)
-
Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non–Small Cell Lung Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-09-19 Anand Swaminath, Sameer Parpia, Marcin Wierzbicki, Vijayananda Kundapur, Sergio Faria, Gordon S. Okawara, Theodoros K. Tsakiridis, Naseer Ahmed, Alexis Bujold, Khalid Hirmiz, Timothy Owen, Nelson Leong, Kevin Ramchandar, Edith Filion, Harold Lau, Zsolt Gabos, Robert Thompson, Brian Yaremko, Selma Mehiri, Alexander V. Louie, Kimmen Quan, Mark N. Levine, James R. Wright, Timothy J. Whelan
ImportanceStereotactic body radiotherapy (SBRT) is widely used for stage I medically inoperable non–small cell lung cancer (NSCLC), yet varied results from randomized clinical trials (RCTs) and concerns in treating centrally located tumors persist.ObjectiveTo examine whether SBRT would improve local control (LC) compared with hypofractionated conventional radiotherapy (CRT).Design, Setting, and ParticipantsThis
-
Standardized Definitions for Efficacy End Points for Adjuvant Trials—The Updated STEEP Criteria JAMA Oncol. (IF 22.5) Pub Date : 2024-09-19 Dominik Hlauschek, Christian Fesl, Michael Gnant
This Viewpoint discusses how the inclusion or exclusion of certain events in the standardization of clinical trial end points can affect the interpretation of results.
-
Accrual to Radiotherapy Trials in the US-Pitfalls and Potential Solutions. JAMA Oncol. (IF 22.5) Pub Date : 2024-09-12 Nina N Sanford,William A Hall
-
Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-09-12 Paolo Tarantino, Gabriel Hortobagyi, Sara M. Tolaney, Elizabeth A. Mittendorf
ImportanceOver the past 2 decades, systemic therapy for early-stage breast cancer has gradually moved from the adjuvant to the neoadjuvant setting. Administration of systemic therapy before surgery leads to potential improvements in surgical outcomes and allows for the assessment of the pathologic response to treatment. For patients with residual disease (RD), 3 adjuvant strategies have been shown
-
Molecular, Socioeconomic, and Clinical Factors Affecting Racial and Ethnic Disparities in Colorectal Cancer Survival JAMA Oncol. (IF 22.5) Pub Date : 2024-09-12 Mahmoud Yousef, Abdelrahman Yousef, Saikat Chowdhury, Mohammad M. Fanaeian, Mark Knafl, Jennifer Peterson, Mohammad Zeineddine, Kristin Alfaro, Fadl Zeineddine, Drew Goldstein, Nicholas Hornstein, Arvind Dasari, Ryan Huey, Benny Johnson, Victoria Higbie, Alisha Bent, Bryan Kee, Michael Lee, Maria Pia Morelli, Van Karlyle Morris, Daniel Halperin, Michael J. Overman, Christine Parseghian, Eduardo Vilar
ImportanceDisparity in overall survival (OS) and differences in the frequency of driver gene variants by race and ethnicity have been separately observed in patients with colorectal cancer; however, how these differences contribute to survival disparity is unknown.ObjectiveTo quantify the association of molecular, socioeconomic, and clinical covariates with racial and ethnic disparities in overall
-
Cervical Cancer Incidence in the US-Affiliated Pacific Islands JAMA Oncol. (IF 22.5) Pub Date : 2024-09-12 Sameer V. Gopalani, Jin Qin, Janos Baksa, Trevor D. Thompson, Mona Saraiya, Virginia Senkomago, Paran Pordell, Youngju Jeong, Neal A. Palafox, Martina Reichhardt, Lee E. Buenconsejo-Lum
ImportanceThe World Health Organization has called for eliminating cervical cancer as a public health problem. Accurate and up-to-date estimates of population-based cervical cancer incidence are essential for monitoring progress toward elimination and informing local cancer control strategies, but these estimates are lacking for the US-Affiliated Pacific Islands (USAPI).ObjectiveTo calculate age-standardized
-
Radiation-Associated Secondary Cancer in Patients With Breast Cancer Harboring TP53 Germline Variants JAMA Oncol. (IF 22.5) Pub Date : 2024-09-12 Gustav Y. Cederquist, Lillian A. Boe, Michael Walsh, Gary M. Freedman, Kara N. Maxwell, Neil Taunk, Lior Z. Braunstein
This cohort study examines the risk of radiation-associated sarcoma in patients with breast cancer harboring germline TP53 variants.
-
Lynch Syndrome and Somatic Mismatch Repair Variants in Pancreas Cancer JAMA Oncol. (IF 22.5) Pub Date : 2024-09-05 Catherine A. O’Connor, Emily Harrold, David Lin, Henry Walch, Andrea Gazzo, Megha Ranganathan, Sarah Kane, Fergus Keane, Joshua Schoenfeld, Drew Moss, Deborah M. Thurtle-Schmidt, Sarah P. Suehnholz, Debyani Chakravarty, Fiyinfolu Balogun, Anna Varghese, Kenneth Yu, David Kelsen, Alicia Latham, Britta Weigelt, Wungki Park, Zsofia Stadler, Eileen M. O’Reilly
ImportanceMicrosatellite (MS) instability (MSI-H) occurs frequently in Lynch syndrome (LS)–associated tumors and is associated with response to immune checkpoint blockade (ICB) therapy. MSI-H is conferred by germline or somatic variants in mismatch repair genes. The contribution of somatic oncogenesis to MSI-H in pancreatic cancer (PC) is unknown.ObjectiveTo evaluate an LS-related PC cohort to define